Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report.
Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report.
复制标题
强化周期性化疗治疗成人急性淋巴细胞白血病：后续报告。
DOI：
10.1182/blood.v78.11.2814.2814
复制
发表时间：
1991
期刊：
影响因子：
20.3
通讯作者：
Ries
中科院分区：
文献类型：
--
作者：
Lee;Levitt;M. O'donnell;Stephen;Forman;Curt;Ries
我们治疗了109例成人急性淋巴细胞白血病（ALL），经组织化学和免疫学技术诊断。仅排除年龄大于50岁和伯基特白血病的患者。治疗包括四种药物缓解诱导期，然后是非交叉耐药化疗和长期口服维持治疗的交替周期。88%的患者完全缓解。中位随访时间为77个月（范围：48 - 111个月），预计42% +/- 6%（SEM）达到缓解的患者在5年时保持无病，所有入组研究的患者的无病生存率为35% +/-5%。在治疗的前4周内未能达到缓解以及费城染色体的存在与100%的复发风险相关。没有这些不良特征的缓解患者有48% +/- 6%的概率保持连续缓解5年。具有T细胞表型的患者预后良好，59% +/- 13%的患者达到缓解，保持无病状态，而CALLA阳性患者的这一比例为31% +/- 7%。强化化疗可延长相当一部分成人ALL患者的无病生存期。需要改进治疗，特别是对于具有不良预后特征的患者。
We treated 109 patients with adult acute lymphoblastic leukemia (ALL) diagnosed by histochemical and immunologic techniques. Patients were excluded only for age greater than 50 years and Burkitt's leukemia. Treatment included a four-drug remission induction phase followed by alternating cycles of noncrossresistant chemotherapy and prolonged oral maintenance therapy. Eighty-eight percent of patients entered complete remission. With a median follow-up of 77 months (range, 48 to 111 months), 42% +/- 6% (SEM) of patients achieving remission are projected to remain disease-free at 5 years, and disease-free survival for all patients entered on study is 35% +/- 5%. Failure to achieve remission within the first 4 weeks of therapy and the presence of the Philadelphia chromosome are associated with a 100% risk of relapse. Remission patients with neither of these adverse features have a 48% +/- 6% probability of remaining in continuous remission for 5 years. Patients with T-cell phenotype have a favorable prognosis with 59% +/- 13% of patients achieving remission remaining disease-free compared with 31% +/- 7% of CALLA-positive patients. Intensive chemotherapy may produce prolonged disease-free survival in a sizable fraction of adults with ALL. Improved therapy is needed, especially for patients with adverse prognostic features.
登录
查看更多内容
成人急性淋巴细胞白血病：爱荷华州 HOP-L 方案的结果。
DOI：
10.1200/jco.1989.7.1.58
发表时间：
1989
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
RadfordJr,JE;Burns,CP;Jones,MP;Gingrich,RD;Kemp,JD;Edwards,RW;McFadden,DB;Dick,FR;Wen,BC
通讯作者：
Wen,BC
儿童急性淋巴细胞白血病核型与免疫表型的相关性。
DOI：
10.1200/jco.1988.6.1.56
发表时间：
1988
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Pui,CH;Williams,DL;Roberson,PK;Raimondi,SC;Behm,FG;Lewis,SH;Rivera,GK;Kalwinsky,DK;Abromowitch,M;Crist,WM
通讯作者：
Crist,WM
影响因子：
11.2
作者：
S. Sallan;S. Hitchcock-bryan;R. Gelber;J. Cassady;E. Frei;D. Nathan
通讯作者：
S. Sallan;S. Hitchcock-bryan;R. Gelber;J. Cassady;E. Frei;D. Nathan
儿童急性淋巴细胞白血病治疗方案的比较分析。
影响因子：
4
作者：
Niemeyer,CM;Hitchcock-Bryan,S;Sallan,SE
通讯作者：
Sallan,SE
影响因子：
4.8
作者：
D. Blaise;Gaspard Mh;Stoppa Am;G. Michel;Gastaut Ja;G. Lepeu;N. Tubiana;Blanc Ap;J. Rossi;G. Novakovitch
通讯作者：
D. Blaise;Gaspard Mh;Stoppa Am;G. Michel;Gastaut Ja;G. Lepeu;N. Tubiana;Blanc Ap;J. Rossi;G. Novakovitch